Alex Therapeutics was founded in 2018 by John Drakenberg (Psychologist) and Oliver Fleetwood (Theoretical Computational Molecular Biophysicist) with a belief that more could be done with psychology and technology to personalize healthcare and support people to change their behavior and improve their quality of life.

With early funding from King (makers of Candy Crush), user-engagement and gamification was in the company's DNA from the beginning, with early products focused on bringing best-in-class consumer product design and user experience together with CBT-based interventions, to provide a digital experience that would be enjoyable, but also result in meaningful health improvement.

After successfully partnering with Pfizer on the development of a CBT-based digital smoking cessation program, the company continued to grow and collaborate with other life sciences companies, becoming the health technology partner of choice for companies looking to build digital therapeutics and therapy companions.

With a modular technology platform providing the foundation for new product development and several years building out the necessary infrastructure and capabilities to deliver regulated digital health products globally, Alex Therapeutics is now leading the way with its use of artificial intelligence and machine learning to enhance the product and user experience.

We are now a dedicated team of 20+ psychologists, engineers, designers, regulatory and market access experts across the EU and US, and we believe that through combining cutting-edge technology with patient-centric design, we can continue to help deliver high-quality, personalized care to millions of people around the world.